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Other names: interleukin 6; interferon beta 2; IL-6; 
HSF; HGF; CDF; BSF2; IFNB2 
Location: 7p15.3 
Local order: cen. - RAPGEF5- LOC221838 - IL6 - 




The gene for IL6 is shown in light blue and comprizes 6 exons 
(with 375 bp, 103 bp, 191 bp, 114 bp, 147 bp and 542 bp in 
length) and 5 introns (with 920 bp, 162 bp, 1058 bp, 707 bp 








The IL6 protein (shown in light green) shares C-terminal a 
homologous region (shown in dark green) also found in IL23A 
and CSF3. 
Description 
212 amino acids, 23.7 kd, containing 4 alpha-helices. 
Homology 
IL6 shares sequence homology with IL23 (IL23A) and 
G-CSF (CSF3). 
Mutations 
Note: G/C polymorphism at nucleotide -174 (promoter 
region)  
Breast cancer prognosis differs between populations. 
Despite its lower incidence in Blacks when compared 
to Caucasians, mortality among the former is higher. 
Genetic factors involved in the molecular pathways 
regulating tumor development have been adduced to 
explain these differences, and it has been suggested that 
the IL-6 gene is a susceptibility factor underlying 
ethnic differences in breast cancer survival. Reports f 
a G/C polymorphism at nucleotide -174 within the 
promoter region of the IL-6 gene support this 
contention. This polymorphism modulates IL-6 
expression and allele/genotype frequencies at the -174
site differ significantly between ethnic groups. 
Implicated in 
Various cancers 
Note: Although IL6 necessary to support growth of 
multiple myeloma cells, and is upregulated in certain 
tumor types, notably lung (squamous), bladder and 
prostate carcinomas, no recurrent chromosome 
rearrangements at 7p21 or IL6 rearrangements have 
been observed in these neoplasms. 
Breast cancer 
Cytogenetics 
No rearrangements reported. 
Oncogenesis 
Some cytokines, including IL-6, stimulate breast cancer 
proliferation or invasion and serve as negative 
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prognostic indicators. Hitherto IL-2, IFNalpha, IFNbeta 
IFNgamma, IL-6, IL-12 have been used for anti tumour 
treatment of advanced breast cancer either to induce or 
increase hormone sensitivity and/or to stimulate 
cellular immunity. Cytokines, such as IL-6 play a key 
role in regulating estrogen synthesis in normal and 
malignant breast tissues. The activities of estradiol 
17beta-hydroxysteroid dehydrogenase and estrone 
sulfatase are all increased by IL-6. Prostaglandin E2 
may also be an important regulator of estradiol activity 
in breast tumors while invading macrophages and 




No rearrangements reported. 
Oncogenesis 
Although interleukin-6 (IL-6) is considered as a key 
growth factor for myeloma cells, only a few 
subpopulations of tumor cells, such as CD45(+) 
immature cells, proliferate in response to IL-6. 
However, increasing numbers of cytokines, 
chemokines and cell-to-cell contacts been support 
growth of MM cells. It has repeatedly shown that 
oncogenic mutations as well as the bone marrow matrix 
(BMM) stimulate IL-6-independent signalling 
pathways that protect MM cells from 
apoptosis.Hyperdiploid MM tumors contain multiple 
trisomies involving chromosomes 3, 5, 7, 9, 11, 15, 19, 
and 21, but rarely have IgH translocations, although 
CCND-1/CCND-2/CCND-3 dysregulation appears to 
occur as an early event. This may sensitize these clls 
to proliferative stimuli, resulting in selective expansion 
as a result of interaction with BMM that produce IL-6 
and other cytokines. 
Three types of growth factors have been identified in 
plasma cells:  
- The IL-6 family cytokines, which activate the Janus 
kinase-signal transducer and activator of transcription 
(JAK/STAT) and mitogen-activated protein (MAP) 
kinase pathways;  
- Growth factors activating the phosphatidylinositol 
(PI)-3 kinase/AKT and MAP kinase pathways, and  
- B-cell-activating factor (BAFF) or proliferation-
inducing ligand (APRIL). 
These growth factors may operate synergetically being 
co-localized together with cytoplasmic transduction 
elements in membrane caveolae. 
Proteasome inhibitors are emerging as a promising 
class of anti-cancer therapeutic agents in MM, e.g. 
bortezomib which inhibits NF-kappaB 
translocation/transcription and critical signalling 




No rearrangements reported. 
Oncogenesis 
IL-6 induces divergent proliferative responses in 
prostate cells. IL-6 is expressed in benign and 
malignant prostate tissue and levels of both IL-6 and 
IL-6R increase during prostate carcinogenesis. Serum 
levels of IL-6 are elevated in patients with treatment-
refractory prostate carcinoma.IL-6 has also been shown 
to promote prostate cell growth, except in LNCaP cells, 
in which arrest and differentiation are produced. IL-6 
induces activation of the androgen receptor (AR) in the 
absence of androgen. IL-6 also modulates vascular 
endothelial growth factor expression and 
neuroendocrine differentiation in prostate cells. Anti-
IL-6 antibodies showed an inhibitory effect on PC-3 
xenografts. Hence, IL-6 is widely considered a 
promising potential therapeutic target in prostate 
cancer. 
Androgen receptor (AR), which is generally expressed 
in prostate cancers, promotes tumor progression in 
various ways, including ligand-independent activation. 
IL-6 is among the most important nonsteroidal 
regulators of AR activity reaching about half the 
maximum levels achieved by AR alone. At low 
concentrations of androgen, IL-6 and androgen operate 
synergistically to activate AR. 
In prostate carcinoma cells homeodomain protein 
GBX2 was identified to contribute directly to IL6 
expression by binding within the promoter region 
containing the consensus sequence for GBX2. 
Hodgkin lymphoma 
Cytogenetics 
No rearrangements detected. 
Oncogenesis 
Hodgkin lymphoma (HL) cells express multiple 
cytokines, notably IL6, which contributes to the 
immunoreactive phenotype and of which high levels 
are associated with bad prognosis. Both transcription 
factors, NFkB and AP1 are constitutively activated in 
in HL cells driving expression of IL6 and also 
disturbing the pro/anti-apoptotic balance. Additionally, 
homeodomain protein HLXB9 contributes to the IL6 
expression. HLXB9 is closely related to homeodomain 
protein GBX2 contributing to IL6 expression in 
prostate carcinoma cells. So, tumor type specific 




No rearrangements reported. 
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Oncogenesis 
Unlike acute inflammation which is a defense respone, 
chronic inflammation may promote cancer. Several 
pro-inflammatory gene products modulate apoptosis, 
proliferation, angiogenesis, invasion, and metastasis, 
including IL-6, which is subject to regulation by NF-
kB, which is constitutively active in most tumors. 
About one-in-three cancer deaths are due to cachexia 
(wasting) following the hypercatabolism of the body's 
carbon sources. Tumor-inflammatory responses 
encompass synthesis of cytokines, including IL-6 
which induces cachexia by altering lipids and protein 
metabolism. IL-6-like cytokines inhibit lipid 
biosynthesis by adipocytes and cause the atrophy and 
increased catabolism of muscle protein. Reduced serum 
IL-6 levels induced by medroxyprogesterone acetate 
has been reported to exert an anti-cachectic effect in 
advanced breast cancer. 
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